FDA Approves FirstinClass Breast Cancer Drug

FDA Approves First-in-Class Breast Cancer Drug

19:27 EDT 27 May 2019 | NEJM

The FDA has approved the first PIK3 inhibitor to treat advanced or metastatic breast cancer. Alpelisib (marketed as Piqray) is approved for use with fulvestrant...

Original Article: FDA Approves First-in-Class Breast Cancer Drug

More From BioPortfolio on "FDA Approves First-in-Class Breast Cancer Drug"